A Study of the Effectiveness of Cabozantinib in Combination With Nivolumab as First-line Treatment of Advanced Renal Cell Carcinoma (aRCC) in Adults
NCT05361434
·
clinicaltrials.gov ↗
ACTIVE_NOT_RECRUITING
Status
311
Enrollment
INDUSTRY
Sponsor class
Conditions
Advanced Renal Cell Carcinoma
Sponsor
Ipsen